Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,032 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluorouracil (5-FU) Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595
View directory record Official record
Conditions
Advanced or Metastatic Colorectal Cancer
Interventions
Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

NCT05307939
View directory record Official record
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01418222
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-FU, FOLFOX regimen, Placebo, bevacizumab [Avastin], leucovorin, onartuzumab [MetMAb]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Fort Myers, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 18, 2026, 1:15 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 18, 2026, 1:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy

NCT00256841
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Chemotherapy, Radiation Therapy
Drug · Procedure
Lead sponsor
Clinical Oncology Research Associates
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 18, 2026, 1:15 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx

NCT00004164
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, docetaxel, fluorouracil, leucovorin calcium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer

NCT00004257
View directory record Official record
Conditions
Esophageal Cancer
Interventions
fluorouracil, oxaliplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 18, 2026, 1:15 AM EDT
Terminated Phase 1 Interventional

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

NCT02648711
View directory record Official record
Conditions
Solid Tumors
Interventions
CRLX101, Bevacizumab, mFOLFOX6
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 18, 2026, 1:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy

NCT04042298
View directory record Official record
Conditions
Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
Interventions
Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw
Other
Lead sponsor
Kansas State University
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 3 Interventional

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

NCT00033735
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, Irofulven
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 18, 2026, 1:15 AM EDT
Active, not recruiting Phase 2 Interventional

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

NCT03784326
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Atezolizumab, Conventional Surgery, Fluorouracil, Oxaliplatin, Tiragolumab
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 1:15 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04642287
View directory record Official record
Conditions
Immunotherapy, Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Organ Transplant Recipients, Skin Cancer
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00721513
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, docetaxel, fluorouracil, computed tomography, positron emission tomography, quality-of-life assessment, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 18, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional Results available

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

NCT04251715
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment
Drug · Device · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 18, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

NCT00009919
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma

NCT00183911
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer
Interventions
floxuridine, 5-Fluorouracil, leucovorin, External Beam Radiotherapy, Surgery
Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer

NCT00003799
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
fluorouracil, oxaliplatin, radiation therapy, leucovorin calcium, therapeutic conventional surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

NCT01966471
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
50
States / cities
Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 18, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional Results available

Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma

NCT02319304
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}, Low dose fractionated radiation therapy (LDFRT)
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 18, 2026, 1:15 AM EDT
Terminated Phase 1 Interventional

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer

NCT04158349
View directory record Official record
Conditions
Colorectal Cancer, Appendiceal Cancer, Peritoneal Carcinoma
Interventions
Oxaliplatin, mFOLFIRI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 18, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

NCT00054977
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
GM-CT-01, 5-fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 18, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers

NCT03800693
View directory record Official record
Conditions
Malignant Digestive System Neoplasm
Interventions
Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 18, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 18, 2026, 1:15 AM EDT
Recruiting Phase 2 Interventional

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

NCT04926467
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Anakinra
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 1:15 AM EDT